Matches in Ghent University Academic Bibliography for { <https://biblio.ugent.be/publication/01JHF5PB1NEED5MVD1H8W5E7TN> ?p ?o. }
Showing items 1 to 42 of
42
with 100 items per page.
- 01JHF5PB1NEED5MVD1H8W5E7TN classification A1.
- 01JHF5PB1NEED5MVD1H8W5E7TN date "2025".
- 01JHF5PB1NEED5MVD1H8W5E7TN language "eng".
- 01JHF5PB1NEED5MVD1H8W5E7TN type journalArticle.
- 01JHF5PB1NEED5MVD1H8W5E7TN hasPart 01JHF5PY4ET1C611DTR03CXNZM.pdf.
- 01JHF5PB1NEED5MVD1H8W5E7TN subject "Biology and Life Sciences".
- 01JHF5PB1NEED5MVD1H8W5E7TN subject "Medicine and Health Sciences".
- 01JHF5PB1NEED5MVD1H8W5E7TN subject "Technology and Engineering".
- 01JHF5PB1NEED5MVD1H8W5E7TN doi "10.1016/j.biopha.2025.117826".
- 01JHF5PB1NEED5MVD1H8W5E7TN issn "0753-3322".
- 01JHF5PB1NEED5MVD1H8W5E7TN issn "1950-6007".
- 01JHF5PB1NEED5MVD1H8W5E7TN volume "183".
- 01JHF5PB1NEED5MVD1H8W5E7TN abstract "Portal hypertension (PH) can cause severe complications in patients with advanced chronic liver disease (aCLD). The pan-peroxisome proliferator-activated receptor (pan-PPAR) agonist lanifibranor reduces portal pressure in preclinical models of aCLD. Since the effect on PH might be secondary to fibrosis improvement, we investigated the effect of lanifibranor on PH, hepatic and splanchnic angiogenesis in mouse models of fibrotic and prehepatic non-fibrotic PH. Mice with fibrotic PH (common bile duct ligation; CBDL) and prehepatic PH (partial portal vein ligation; PPVL) received daily lanifibranor/vehicle for 14 or 7 days, respectively. Hemodynamics, serum, hepatic and mesenteric histology, and hepatic, mesenteric and liver sinusoidal endothelial cells (LSEC) gene expression levels were analyzed. Vascular corrosion casts of the venous mesenteric and hepatic vasculature were analyzed using scanning electron microscopy and µCT. Portal pressure was increased in CBDL mice. Lanifibranor treatment demonstrated a dose-dependent trend towards decreasing the elevated portal pressure, and reduced fibrosis. Hepatic mRNA levels of inflammatory, fibrotic and angiogenic markers were significantly downregulated in lanifibranor-treated CBDL mice. LSEC dysfunction was improved by lanifibranor. Compared to CBDL mice, portal pressure was more extensively elevated in PPVL mice, which was significantly reduced by lanifibranor. Superior mesenteric artery blood flow, which was increased in vehicle-treated PPVL mice, tended to decrease by lanifibranor. The expansion of the mesenteric vasculature and mesenteric protein level of angiogenetic markers in PPVL mice were reduced after lanifibranor. In conclusion, lanifibranor improves PH, independently from fibrosis reduction, potentially through reducing the venous mesenteric vasculature expansion and intrahepatic angiogenesis, and ameliorating LSEC function.".
- 01JHF5PB1NEED5MVD1H8W5E7TN author 00391288-F0EE-11E1-A9DE-61C894A0A6B4.
- 01JHF5PB1NEED5MVD1H8W5E7TN author 00789E08-F0EE-11E1-A9DE-61C894A0A6B4.
- 01JHF5PB1NEED5MVD1H8W5E7TN author 02B63C5A-8110-11E6-A481-131EB5D1D7B1.
- 01JHF5PB1NEED5MVD1H8W5E7TN author 04CFB180-F0EE-11E1-A9DE-61C894A0A6B4.
- 01JHF5PB1NEED5MVD1H8W5E7TN author 0908DEFC-F0EE-11E1-A9DE-61C894A0A6B4.
- 01JHF5PB1NEED5MVD1H8W5E7TN author 1340021A-F0EE-11E1-A9DE-61C894A0A6B4.
- 01JHF5PB1NEED5MVD1H8W5E7TN author 2737836A-F0EE-11E1-A9DE-61C894A0A6B4.
- 01JHF5PB1NEED5MVD1H8W5E7TN author 2A25CC1C-F0EE-11E1-A9DE-61C894A0A6B4.
- 01JHF5PB1NEED5MVD1H8W5E7TN author 31BD9BF8-F0EE-11E1-A9DE-61C894A0A6B4.
- 01JHF5PB1NEED5MVD1H8W5E7TN author 46fc16f1-7464-11ea-8d7b-da85d9cb4acd.
- 01JHF5PB1NEED5MVD1H8W5E7TN author F471AE56-F0ED-11E1-A9DE-61C894A0A6B4.
- 01JHF5PB1NEED5MVD1H8W5E7TN author F7ACF21A-F0ED-11E1-A9DE-61C894A0A6B4.
- 01JHF5PB1NEED5MVD1H8W5E7TN author F7B82B3A-F0ED-11E1-A9DE-61C894A0A6B4.
- 01JHF5PB1NEED5MVD1H8W5E7TN author FE9901FE-F0ED-11E1-A9DE-61C894A0A6B4.
- 01JHF5PB1NEED5MVD1H8W5E7TN author urn:uuid:05259d60-0500-4f25-abc0-3b26142c4cdb.
- 01JHF5PB1NEED5MVD1H8W5E7TN author urn:uuid:c8c56892-23f0-4508-b06e-e87d2adadfc3.
- 01JHF5PB1NEED5MVD1H8W5E7TN dateCreated "2025-01-13T06:30:20Z".
- 01JHF5PB1NEED5MVD1H8W5E7TN dateModified "2025-01-31T10:29:15Z".
- 01JHF5PB1NEED5MVD1H8W5E7TN name "The pan-PPAR agonist lanifibranor reduces portal pressure independent of fibrosis reduction through the splanchnic vasculature".
- 01JHF5PB1NEED5MVD1H8W5E7TN pagination urn:uuid:0a9c5252-941e-49ed-8d8d-cb578c862f5e.
- 01JHF5PB1NEED5MVD1H8W5E7TN sameAs LU-01JHF5PB1NEED5MVD1H8W5E7TN.
- 01JHF5PB1NEED5MVD1H8W5E7TN sourceOrganization urn:uuid:2f47f280-da73-4337-86c3-10f80e3fd828.
- 01JHF5PB1NEED5MVD1H8W5E7TN sourceOrganization urn:uuid:3b9d1b2d-c9c2-48a0-b790-58eb09fec8d3.
- 01JHF5PB1NEED5MVD1H8W5E7TN sourceOrganization urn:uuid:5d8df0d9-494e-4558-b375-e971d2aeddd8.
- 01JHF5PB1NEED5MVD1H8W5E7TN sourceOrganization urn:uuid:9ddc6e01-9b63-455f-977f-80d33348b3dc.
- 01JHF5PB1NEED5MVD1H8W5E7TN sourceOrganization urn:uuid:a938db61-b4e1-4fa9-8365-c79cb33ef101.
- 01JHF5PB1NEED5MVD1H8W5E7TN sourceOrganization urn:uuid:b753ecf4-472d-46d7-9235-eb11de72d47a.
- 01JHF5PB1NEED5MVD1H8W5E7TN sourceOrganization urn:uuid:f77fb129-1b88-4041-b25c-d0f190085748.
- 01JHF5PB1NEED5MVD1H8W5E7TN type A1.